1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bayer Pharma Aktiengessellschaft has 1 pending office action currently under review. This matter is distributed across 1 distinct examiner and 1 distinct art unit, reflecting a narrow point of contact with the patent office. DIAMOND, ALAN D is the busiest examiner for the portfolio, holding 1 busiest examiner pending action. Since the total pending office actions is 1, this individual manages the entire active docket for the company, allowing for a focused prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18514674 | Process for Preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and Purification Thereof for Use as a Pharmaceutical Active Ingredient | DIAMOND, ALAN D | 3991 | Other | Non-Final OA | — | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBayer Pharma Aktiengessellschaft has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alan D Diamond has the most, with 1 of Bayer Pharma Aktiengessellschaft's pending office actions.
